Derivation Web

source_1306d0ffe025425a

by researka:v2 · 2026-07-18 01:04:33.259205+04:00

# Research Synthesis: Influenza Vaccination Effects — full paper

## Abstract

Evidence-honesty note: 41/53 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Annual influenza vaccination is widely recommended for older adults and high-risk populations, yet the breadth of its reported clinical effects — from cardiovascular event reduction to all-cause mortality, hospitalization, dementia prevention, and uptake itself — remains unevenly characterized across outcomes and study designs.

We conducted an AI-assisted structured evidence synthesis with full audit trail, extracting effect-direction, directness, and design from 53 curated sources spanning randomized trials, propensity-matched cohorts, target-trial emulations, and umbrella reviews, integrating across cardiovascular, mortality, longevity, immune, and uptake outcomes.

The evidence profile indicates that influenza vaccination is supported by consistent context-specific cardiometabolic and longevity signals in observational and umbrella-review syntheses, but coverage deficits, inconsistent dose effects, and a partially positive-versus-null mortality literature mean that boundary conditions — population, dose, and design — remain is consistent with before mechanistic plausibility can be claimed as clinically demonstrated.

**Evidence-abstraction note.** The 53 retained reference papers are not 53 independent primary clinical trials: 41 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 12 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Research Question

Within the retained source corpus for influenza vaccination effects, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on influenza vaccination effects across 53 included source papers and 1764 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 12 direct clinical sources, 41 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for influenza vaccination effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Chen 2025, Yingyounyong 2025, Wang 2025a are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. [bundle:5] [bundle:8] [bundle:10]

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the longevity, cardiometabolic and contextual adjacent evidence outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-influenza_vaccination_effects-v06-DAILY-2026-07-17T20-52-39Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-17.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `influenza vaccination effects aging`
- `influenza vaccination effects older adults`
- `influenza vaccination effects randomized controlled trial`
- `influenza vaccination aging`
- `influenza vaccination older adults`
- `influenza vaccination randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses influenza vaccination effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 177 records in the receipt-candidate union, 57 were classified as source candidates and 53 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 177 |
| Classified source candidates | 57 |
| No extractable claims | 11 |
| None-only claim binding | 8 |
| Mixed partial-or-none claim-binding candidates | 85 |
| Partial-only claim-binding candidates | 10 |
| Strict high-confidence sources | 6 |
| Admitted final sources | 53 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 53 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Chiu 2025: Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:27]
| Cardiometabolic | Dehesh 2025: Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:39]
| Cardiometabolic | Guo 2025: Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding | [bundle:4]
| Cardiometabolic | Jin 2026: Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=43 extracted claim(s); source-level direction is the coded finding | [bundle:17]
| Cardiometabolic | Pedersen 2024: INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes | direction=null | directness=protocol | D1 | outcome=Cardiometabolic; direction=null | finding=36 extracted claim(s); source-level direction is the coded finding | [bundle:18]
| Cardiometabolic | Tadount 2025: Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=52 extracted claim(s); source-level direction is the coded finding | [bundle:11]
| Cardiometabolic | Wang 2025c: Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:15]
| Cardiometabolic | Wei 2026: The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.20; not treated as positive or negative directional support unless source direction is coded | [bundle:22]
| Cardiometabolic | Yang 2024: Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=57 extracted claim(s); source-level direction is the coded finding | [bundle:9]
| Cardiometabolic | Yang 2025: Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding | [bundle:42]
| Contextual Adjacent Evidence | Alshagrawi 2025: Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:19]
| Contextual Adjacent Evidence | Alshahrani 2025: Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj | direction=mixed | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.37; not treated as positive or negative directional support unless source direction is coded | [bundle:30]
| Contextual Adjacent Evidence | Andrew 2004: Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.0007; source-level statistic reported | [bundle:53]
| Contextual Adjacent Evidence | Blandi 2026: From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding | [bundle:51]
| Contextual Adjacent Evidence | Chaves 2026: Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022 | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding | [bundle:26]
| Contextual Adjacent Evidence | Chen 2025: Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:5]
| Contextual Adjacent Evidence | Fortunato 2025: Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023 | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:6]
| Contextual Adjacent Evidence | Hansen 2025: Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:38]
| Contextual Adjacent Evidence | Hu 2024: Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.02; source-level statistic reported | [bundle:29]
| Contextual Adjacent Evidence | Katangwe-Chigamba 2025: Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.045; source-level statistic reported | [bundle:43]
| Contextual Adjacent Evidence | Krishnan 2026: Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:23]
| Contextual Adjacent Evidence | Li 2025: Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=22 extracted claim(s); source-level direction is the coded finding | [bundle:33]
| Contextual Adjacent Evidence | Lin 2024: Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=14 extracted claim(s); source-level direction is the coded finding | [bundle:41]
| Contextual Adjacent Evidence | McConeghy 2025: Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:32]
| Contextual Adjacent Evidence | Mora 2025: Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=19 extracted claim(s); source-level direction is the coded finding | [bundle:37]
| Contextual Adjacent Evidence | Pagkozidis 2026: Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding | [bundle:46]
| Contextual Adjacent Evidence | Papagiannis 2024: Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:21]
| Contextual Adjacent Evidence | Rocinova 2026: Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review | direction=positive | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:20]
| Contextual Adjacent Evidence | Szilagyi 2025: Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.06; not treated as positive or negative directional support unless source direction is coded | [bundle:13]
| Contextual Adjacent Evidence | Wang 2024: Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=26 extracted claim(s); source-level direction is the coded finding | [bundle:28]
| Contextual Adjacent Evidence | Wang 2025a: A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:10]
| Contextual Adjacent Evidence | Wang 2025b: Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.048; source-level statistic reported | [bundle:14]
| Contextual Adjacent Evidence | Wang 2026: Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=21 extracted claim(s); source-level direction is the coded finding | [bundle:35]
| Contextual Adjacent Evidence | Wright 2025: Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial | direction=mixed | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.435; not treated as positive or negative directional support unless source direction is coded | [bundle:12]
| Contextual Adjacent Evidence | Xie 2024: Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:48]
| Contextual Adjacent Evidence | Zhang 2024: Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=9 extracted claim(s); source-level direction is the coded finding | [bundle:44]
| Dosing and Pharmacokinetics | Bonduelle 2025: Boosting effect of high-dose influenza vaccination on innate immunity among elderly | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:40]
| Dosing and Pharmacokinetics | Bukhbinder 2026: Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination | direction=null | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:31]
| Dosing and Pharmacokinetics | Wen 2025: Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | [bundle:3]
| Frailty | Espersen 2025b: Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial | direction=positive | directness=direct | A1 | outcome=Frailty; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:25]
| Immune and Inflammation | Abbasian 2025: Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:47]
| Immune and Inflammation | Yingyounyong 2025: A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study | direction=unclear | directness=direct | A1 | outcome=Immune and Inflammation; direction=unclear | finding=representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded | [bundle:8]
| Longevity | Alotaibi 2026: Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P = 0.004; source-level statistic reported | [bundle:34]
| Longevity | Appel 2025: The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=44 extracted claim(s); source-level direction is the coded finding | [bundle:16]
| Longevity | Hosseini 2026: Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:49]
| Longevity | Incalzi 2024: Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion | direction=null | directness=review | B2 | outcome=Longevity; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding | [bundle:52]
| Longevity | Leung 2025: The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:36]
| Longevity | Liu 2025: Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=7 extracted claim(s); source-level direction is the coded finding | [bundle:45]
| Longevity | Luo 2026: Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study | direction=null | directness=indirect | B2 | outcome=Longevity; direction=null | finding=representative non-significant statistic P = 0.838; not treated as positive or negative directional support unless source direction is coded | [bundle:7]
| Longevity | Streeter 2022: Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:50]
| Mortality and Survival | Sun 2025: Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study | direction=positive | directness=indirect | B2 | outcome=Mortality and Survival; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:1]
| Safety and Comorbidity | Espersen 2025a: Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial | direction=positive | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:2]
| Safety and Comorbidity | Jiang 2025: Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:24]

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Influenza Vaccination Effects / Contextual Adjacent Evidence | n=26; claims=745 | significant source statistic in 13/26 sources; receipt-level direction coded null | 10 direct; 13 indirect; 3 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Cardiometabolic | n=10; claims=396 | significant source statistic in 2/10 sources; receipt-level direction coded null | 4 indirect; 1 protocol; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Longevity | n=8; claims=163 | positive signal in 5/8 sources | 3 indirect; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Dosing and Pharmacokinetics | n=3; claims=131 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Immune and Inflammation | n=2; claims=64 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Safety and Comorbidity | n=2; claims=128 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Frailty | n=1; claims=31 | positive signal in 1/1 sources | 1 direct | single-source slice; hypothesis-generating |
| Influenza Vaccination Effects / Mortality and Survival | n=1; claims=106 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Infectious-disease and immunology context: 52 sources; significant source statistic in 22/52 sources; receipt-level direction coded null.
- Oncology and cancer context: 1 sources; positive signal in 1/1 sources.

### Results Summary

- Contextual Adjacent Evidence: n=26; claims=745; no extracted directional signal in 13/26 sources | directness: 10 direct; 13 indirect; 3 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=10; claims=396; no extracted directional signal in 5/10 sources | directness: 4 indirect; 5 review; 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=8; claims=163; benefit signal in 5/8 sources | directness: 3 indirect; 5 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=3; claims=131; mixed signal in 2/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=2; claims=64; mixed signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Safety and Comorbidity: n=2; claims=128; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Across the cardiometabolic outcome class, the corpus is dominated by observational cohorts and umbrella or systematic reviews rather than large randomized trials. Endpoint categories recur across these sources and include all-cause mortality, MACE, myocardial infarction, stroke, ICU admission, liver cancer incidence, and influenza vaccination coverage itself.

Mechanistically, the cardiometabolic findings cluster around plausible non-respiratory pathways — inflammatory stabilization around the index vaccination window, reduced triggering of acute coronary and cerebrovascular events by averted respiratory infection, and modulation of chronic-disease trajectories. Jin 2026 cites a self-controlled case-series observation that within the first 7 days after laboratory-confirmed influenza, patients experienced elevated cardiovascular and respiratory event rates, providing a mechanistic substrate for the protective associations seen in Wei 2026 and Tadount 2025. Preclinical data are not represented as a separate evidence stream within this outcome class; instead, the human cohort and review literature carries both the mechanistic framing and the effect estimates. [bundle:11] [bundle:17] [bundle:22]

Within-corpus tensions in the cardiometabolic class reflect differences in directness, population, and design rather than flat contradictions. Effect-direction tags also diverge across sources — positive in Chiu 2025 and Wang 2025c, null in Yang 2024 and Dehesh 2025, and unclear in Guo 2025, Jin 2026, and Wei 2026 — reflecting genuine uncertainty about magnitude and generalizability rather than a single resolved estimate. The protocol-stage INVITED trial (Pedersen 2024) and the IVCAD randomized study (Dehesh 2025) signal that the field is moving toward placebo-controlled designs that can adjudicate these observational disagreements. [bundle:4] [bundle:9] [bundle:15] [bundle:17] [bundle:18] [bundle:22] [bundle:27] [bundle:39]

### Contextual Adjacent Evidence Outcomes

Across the corpus, the contextual other outcome class subsumes heterogeneous endpoints spanning vaccine coverage, behavioral nudges, health-literacy interventions, and downstream morbidity proxies. Mechanistically, completed RCTs (Wang 2024, Xie 2024, Zhang 2024) furnish protocols whose central tendency on uptake has not yet accrued endpoint values, so this class is reported predominantly through protocol-level denominators rather than confirmed effect sizes. [bundle:28] [bundle:44] [bundle:48]

Quantitative findings cluster into three themes: coverage epidemiology, intervention efficacy, and morbidity correlates.

Mechanistically, the contextual other pathway is dominated by behavioral, educational, and access-modifying interventions rather than molecular or immunological mechanisms, drawing on clinical RCTs of nudges, education, and incentive structures (Wang 2024, Wright 2025, Lin 2024, Li 2025, Hansen 2025, Katangwe-Chigamba 2025, Wang 2025a, Chen 2025), mechanistic/biomarker-adjacent observational human cohorts (Hu 2024, Szilagyi 2025, Mora 2025, Fortunato 2025, Chaves 2026, McConeghy 2025, Wang 2026, Pagkozidis 2026, Blandi 2026), and synthetic reviews (Alshagrawi 2025, Papagiannis 2024, Rocinova 2026) as their mechanistic substrate. Mechanistically, the preventive pathway operates through raising perceived risk and reducing logistical friction (Wang 2025b, Szilagyi 2025), while the cognitive pathway operates through health-literacy improvement (Chen 2025, Xie 2024). Preclinical data do not apply to this outcome class, which by definition tracks behavioral and coverage endpoints. Within-corpus reviews (Alshagrawi 2025, Papagiannis 2024, Rocinova 2026) and protocol-stage RCTs (Wang 2024, Xie 2024, Hansen 2025, Lin 2024, Li 2025, Zhang 2024) jointly illustrate the mechanistic interdependence between access/logistic interventions and cognitive/educational interventions within the contextual other class. [bundle:5] [bundle:6] [bundle:10] [bundle:12] [bundle:13] [bundle:14] [bundle:19] [bundle:20] [bundle:21] [bundle:26] [bundle:28] [bundle:29] [bundle:32] [bundle:33] [bundle:35] [bundle:37] [bundle:38] [bundle:41] [bundle:43] [bundle:44] [bundle:46] [bundle:48] [bundle:51]

Within-corpus tensions in the contextual other class are surfaced chiefly along the directness axis. The same divide separates Xie 2024, Zhang 2024, Lin 2024, Hansen 2025, Wright 2025, Chen 2025, Li 2025, Katangwe-Chigamba 2025, and Wang 2025a from the indirect literature. The source therefore documents both strongly significant and clearly null contrasts within a single trial design, with no single overall directional label. [bundle:5] [bundle:10] [bundle:12] [bundle:33] [bundle:38] [bundle:41] [bundle:43] [bundle:44] [bundle:48]

Within-corpus tension is therefore best framed as disagreement on whether dose escalation produces durable clinical or immunologic benefit, not as a uniform null across the three sources. The trial framework is the canonical high-dose versus standard-dose head-to-head design, with the post hoc re-stratification supplying the frailty-specific endpoint rather than the primary trial. Effect sizes and follow-up windows are reported per the source and not recomputed here.

Because the cross-study disagreement map contains no same-outcome non-orthogonal pairs for frailty, no internal disagreement between sources needs to be adjudicated; the relevant interpretive tension is between the strength of the primary signal and the fragility of the secondary estimates. This positions influenza vaccination in frail / sarcopenic adults as a setting with a clear overall direction but boundary conditions that still require confirmation.

### Immune and Inflammation Outcomes

Yingyounyong 2025 is an open-labeled randomized controlled study comparing booster-dose (BD) versus standard-dose (HI) inactivated influenza vaccination in adults with systemic lupus erythematosus, with hemagglutination-inhibition (HAI) titer seroconversion as the mechanistic/biomarker primary endpoint. After the booster dose, HAI titer rates at the ≥1:160 cut point were increased in all strains, approaching 100%, similar to the HI group, and the upper-respiratory symptom burden was numerically reduced in the BD arm. The trial was designed to test whether an additional antigenic exposure could close the immunogenicity gap that has historically been reported in lupus patients receiving standard-dose vaccine. [bundle:8]

Two formally tested contrasts in Yingyounyong 2025 produced divergent statistical signals. The HAI geometric mean titer comparison between BD and HI arms did not achieve the conventional significance threshold (P = 0.064), whereas the upper-respiratory symptom score comparison crossed it (P = 0.008) in favor of the booster dose. The directional reading of the biomarker contrast is therefore unclear, while the clinical-symptom contrast is favorable to BD. No additional p-values, sample sizes, or follow-up durations were extractable from the indexed excerpts, so the quantitative profile is anchored on these two statistics and the categorical ≥1:160 seroprotection rate. [bundle:8]

Mechanistically, the BD arm appears to compensate for the lupus-associated blunting of vaccine responses by delivering a second antigenic exposure, after which HAI titers at the ≥1:160 cut point approached 100% across strains and converged with the standard-dose response. Preclinical data from related lupus immunization models — though not part of the indexed corpus — would be required to localize the deficit in antigen presentation, T-follicular help, or B-cell memory; within this evidence base the mechanism is inferred only from the convergence of post-booster seroprotection rates across arms. The dissociation between the null titer contrast (P = 0.064) and the positive symptom contrast (P = 0.008) suggests that the booster's clinical benefit may not be fully captured by peak HAI titer alone, consistent with broader literature indicating that HAI magnitude is an imperfect surrogate for influenza illness protection.

Readers should note that the open-label design, the absence of a reported sample size, and the lack of a follow-up duration in the indexed excerpts all constrain inference. The design is observational cohort rather than clinical RCT, the exposure is seasonal influenza vaccination, and the endpoint is incident COVID-19. Because the outcome measured is infection rather than a canonical immune or inflammatory biomarker panel, the immune inflammation label applies only as an indirect mechanistic surrogate, consistent with the source-level indirect directness flag (Abbasian 2025). [bundle:47]

Quantitative findings are limited to a hazard ratio framing: after adjusting for confounding variables, the calculated Hazard Ratio indicated that influenza vaccination has no significant effect on the outcome variable (Abbasian 2025). No exact HR, confidence interval, or p-value is reported in the available source excerpts, so the numeric summary is restricted to the qualitative null direction flagged in the source (Abbasian 2025; effect direction: unclear on the raw scale, with the adjusted inference reading as null). Because the evidence synthesis carries per-study endpoint evidence and the single immune inflammation entry contains no parsed p-value, the prose here references rather than restates a quantitative tuple. [bundle:47]

Mechanistically, an indirect connection between influenza vaccination and downstream infectious or inflammatory sequelae is plausible via trained innate immunity and transient interferon-mediated antiviral states, but the Abbasian 2025 cohort does not measure these substrates. As an observational cohort in adults, the study sits below clinical RCT evidence in the inferential hierarchy and above preclinical data, so any mechanistic claim in this paragraph remains an inference from the indirect directness label rather than a measured pathway (Abbasian 2025). The corpus therefore does not yet contain a mechanistic human substudy interrogating cytokine, antibody titre, or cellular recall response to influenza vaccination in older adults. [bundle:47]

Within-corpus tensions in the immune inflammation class are constrained by the single-source evidence base: there is no second immune inflammation source to disagree with Abbasian 2025, and the cross-study disagreement map records no non-orthogonal pair for this outcome class. The integrating thesis flags that the broader Influenza case is incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence, and the immune inflammation class is the clearest illustration of that sparseness — exactly one indirect observational cohort with a null adjusted association and no parsed p-value (Abbasian 2025). [bundle:47]

### Longevity Outcomes

Eight curated studies populate the longevity outcome class, spanning observational cohorts, a retrospective cohort in ICU-admitted adults, and several systematic reviews or meta-analyses of randomized controlled trials. Luo 2026 examined delayed influenza vaccination within 14 days of ICU admission in adults as a retrospective cohort design, while Appel 2025 evaluated the effect of influenza vaccination on hospitalization and mortality among people with dementia in an observational cohort. Four pooled analyses (Alotaibi 2026; Liu 2025; Streeter 2022; Hosseini 2026) aggregated RCT evidence across cardiovascular and older-adult populations, with endpoint constructs ranging from major adverse cardiovascular events (MACE) to all-cause and cardiovascular mortality. [bundle:7] [bundle:16] [bundle:34] [bundle:45] [bundle:49] [bundle:50]

Mechanistically, the longevity signal in pooled cardiovascular RCTs (Alotaibi 2026; Liu 2025; Streeter 2022; Hosseini 2026) is plausibly mediated by attenuation of acute respiratory infection-triggered systemic inflammation and prothrombotic surges in patients with established atherosclerosis — a substrate that mechanistic human studies and the broader cardiovascular literature link to plaque destabilization. By contrast, in the ICU-admitted population of Luo 2026, the mechanistic substrate may be inverted: critically ill patients already harbor an activated inflammatory cascade, so a vaccination exposure delivered within 14 days of ICU admission is unlikely to attenuate an established acute illness, which is consistent with the uniformly non-significant p-values reported. [bundle:7] [bundle:34] [bundle:45] [bundle:49] [bundle:50]

Within-corpus tensions are most visible between the cardiovascular pooled reviews and the null ICU-cohort signal. This partial conflict with Incalzi 2024 — which, as a narrative review of elderly, vulnerable, and high-risk subjects, did not surface a uniform mortality benefit — and with Luo 2026 — where no examined ICU endpoint achieved statistical significance — indicates that the protective longevity signal is conditional on the underlying baseline risk window. In community-dwelling cardiovascular patients the signal is reproducible across Alotaibi 2026, Liu 2025, Streeter 2022, and Hosseini 2026; in acutely ICU-admitted adults the signal is absent in Luo 2026. This pattern is compatible with a boundary condition defined by illness acuity at the time of vaccine administration rather than a true contradiction across the evidence base. [bundle:7] [bundle:34] [bundle:45] [bundle:49] [bundle:50] [bundle:52]

### Mortality and Survival Outcomes

A single observational cohort study from the Center for Disease Control and Prevention of Shenzhen, Guangdong, China, examined 2017–2019 data comparing current-season-only versus continuous two-season influenza vaccination in older adults using a propensity-score-matched retrospective design. The endpoint of interest was all-cause mortality within the vaccinated older-adult population, framed against a backdrop of seasonal vaccine policy debates. The source documents a structured analysis with multiple stratified comparisons, yielding several statistically meaningful contrasts alongside a non-significant one. This design is positioned as indirect because exposure is the contrast between vaccination strategies rather than vaccination versus no vaccination per se, but the outcome class (mortality) remains directly clinically meaningful (Sun 2025). [bundle:1]

Mechanistically, the plausibility of a continuous two-season advantage aligns with cumulative immunologic priming against drifted strains and reduced inter-season susceptibility windows in older adults, whose vaccine responses are attenuated by immunosenescence (Cruz-Jentoft 2019). The source, however, is observational rather than a clinical RCT, leaving residual confounding by health-seeking behavior and functional status as plausible alternative explanations. Because the only available evidence for this outcome class is a single indirect observational cohort, the mechanistic substrate for the mortality differential remains inferential rather than directly demonstrated. Preclinical or mechanistic human data on repeated-season antigenic exposure are not represented in the corpus for this outcome class.

Within the corpus, Sun 2025 stands alone for the mortality survival outcome class, so there are no within-outcome disagreements to surface here. [bundle:1]

The broader synthesis tension described in the brief — that positive longevity signals coexist with sparse mechanistic anchoring — applies: this single propensity-score-matched study supplies the positive signal, while no complementary clinical RCT or mechanistic human study anchors the pathway.

Together these studies define a safety-comorbidity signal that is operationalized through behavioral-electronic and behavioral-psychological levers rather than through traditional pharmacovigilance endpoints.

### Dosing and Pharmacokinetics Outcomes

Mechanistically, the Bonduelle 2025 outcome class sits at the intersection of dosing and innate-immunity recall — a pathway by which a higher antigenic load in elderly recipients could plausibly amplify trained-immunity outputs, and the P = 0.03 to P < 0.01 spread of contrasts is consistent with partial, not uniform, boosting. Bukhbinder 2026 occupies a different mechanistic lane: the H-IIV → lower AD risk hypothesis (Bukhbinder 2026) presumes either reduced influenza-mediated neural injury or a direct antigenic effect on microglial activation, both of which would be expected to act over months rather than days. [bundle:31] [bundle:40]

Dosing and Pharmacokinetics remains a separate Results slice for Influenza Vaccination Effects (n=3; claims=131; significant source statistic in 2/3 sources; source-level direction coded unclear; 3 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Safety and Comorbidity Outcomes

Espersen 2025a reports a prespecified analysis of the nationwide randomized NUDGE-FLU-CHRONIC trial, in which electronic nudges were deployed to adults with atrial fibrillation to increase influenza vaccination uptake. [bundle:2]

The endpoint was vaccination behavior, and the population included younger and middle-aged individuals with atrial fibrillation — a population in whom the safety-comorbidity interface is anchored by underlying arrhythmia rather than frailty (Espersen 2025a). [bundle:2]

Jiang 2025 contributes a COM-B model–based meta-analysis examining barriers to influenza vaccination in older adults with chronic diseases, framing capability, opportunity, and motivation as upstream determinants of uptake (Jiang 2025). [bundle:24]

Quantitative findings in this outcome class are anchored to specific source values rather than pooled estimates. Espersen 2025a reports P < 0.001 for at least one primary contrast and P = 0.027 for a secondary comparison, supporting a directional — though review-tagged as unclear — effect of electronic nudges on uptake in atrial fibrillation (Espersen 2025a). No p-values were extracted for the Jiang 2025 meta-analysis, so effect-size magnitude is reported without an inferential statistic. These numerics can be interpreted as per-study endpoint evidence rather than as a pooled effect, and the evidence synthesis preserves the original study × statistic tuples. [bundle:2] [bundle:24]

Mechanistically, both studies position vaccination uptake — rather than a hard clinical safety endpoint — as the proximal outcome that mediates downstream comorbidity effects. In a clinical RCT design, the Espersen 2025a trial operationalizes the mechanism as a low-cost behavioral-electronic nudge delivered at scale to a chronic-disease registry, with downstream safety-comorbidity benefit implicitly mediated through higher coverage. The convergence of the two mechanistic frames — electronic delivery and COM-B barriers — implies that safety-comorbidity risk from low coverage is modifiable through distinct, complementary human-study pathways rather than through any single intervention channel. [bundle:2]

Within-corpus tensions in this outcome class are modest because both curated entries point in a coherent direction. Espersen 2025a reports significant effects on vaccination behavior (P < 0.001; P = 0.027) in atrial fibrillation, while Jiang 2025 identifies COM-B barriers that, if unaddressed, would be expected to attenuate any electronic-nudge effect in older adults with chronic disease (Espersen 2025a; Jiang 2025). This within-corpus disagreement is best framed as a population-boundary question rather than a contradiction of effect direction, and it dovetails with the broader synthesis claim that boundary conditions for influenza vaccination effects remain to be established (Espersen 2025a; Jiang 2025). [bundle:2] [bundle:24]

### Frailty Outcomes

Frailty remains a separate Results slice for Influenza Vaccination Effects (n=1; claims=31; positive signal in 1/1 sources; 1 direct; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Espersen 2025b (Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1). [bundle:25]

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. For influenza vaccination effects, direct sources such as Chen 2025, Yingyounyong 2025, Wang 2025a define the human evidence perimeter, while mechanistic sources such as the retained evidence base explain why an effect could occur. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism. [bundle:5] [bundle:8] [bundle:10]

Divergence is equally informative. Positive signals represented by Sun 2025, Wang 2025c, Appel 2025 occur alongside null signals represented by Luo 2026, Yang 2024, Tadount 2025 and negative or adverse signals represented by the retained evidence base. Their outcome distribution spans the longevity, cardiometabolic and contextual adjacent evidence outcome classes, the contextual adjacent evidence, cardiometabolic and longevity outcome classes, and no dominant outcome class. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently. [bundle:1] [bundle:7] [bundle:9] [bundle:11] [bundle:15] [bundle:16]

 These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 53 curated reference papers, the evidence base for influenza vaccination effects shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The influenza vaccination effects broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 53 curated reference papers, the evidence base for Influenza shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Influenza broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 53 included sources. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; type 2 diabetes patients; older adults; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is heavily weighted toward observational cohort studies and protocol-stage randomized trials, which limits the conclusions that can be drawn about hard clinical endpoints. This asymmetry between positive meta-analytic point estimates and heterogeneous primary-trial results is itself a limitation of the available evidence base.

Population specificity further narrows the external validity of the synthesis. These coverage gradients imply that any pooled effect estimate is averaging over settings where baseline vaccination probability differs by orders of magnitude.

Endpoint scope is unevenly represented. The dominant outcome class in the corpus is contextual other, and many of the direct RCTs (e. For example, Wang 2024, Wang 2025a) measure vaccination uptake rather than clinical protection. Consequently, the synthesis cannot resolve how much of the apparent mortality benefit observed in indirect studies is mediated by prevented influenza illness versus by non-specific effects on cardiovascular or inflammatory pathways. [bundle:10] [bundle:28]

A substantial mechanism-to-clinic gap exists for several non-influenza endpoints where the corpus contains primarily mechanistic or biomarker-level data. Per Ioannidis 2005, surrogate and mechanistic associations do not guarantee hard-outcome validity, so these signals can be interpreted as hypothesis-generating rather than as established clinical benefit within the limits of this corpus.

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 53 included sources. Effect directions are null (n=22), unclear (n=19), positive (n=11), mixed (n=1), with 25 sources carrying source-traced p-values and 494 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 53 included sources on Influenza Vaccination Effects across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Incalzi 2024 and Alotaibi 2026 on longevity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. [bundle:34] [bundle:52]

Prior reviews in the corpus (Alotaibi 2026, Liu 2025, Streeter 2022, Hosseini 2026) emphasize convergent signals on Influenza Vaccination Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. [bundle:34] [bundle:45] [bundle:49] [bundle:50]

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 8 | mixed, null, positive | conflict-resolution gap |
| cardiometabolic | 0 | 10 | null, positive, unclear | direct interventional hard-endpoint gap |
| frailty | 1 | 0 | positive | replication gap |
| dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 1 | unclear | replication gap |
| mortality and survival | 0 | 1 | positive | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 10 | 16 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: conflict-resolution gap | 0 direct and 8 indirect sources; direction profile: mixed, null, positive |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 10 indirect sources; direction profile: null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 0 indirect source; direction profile: positive |
| P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P5 | immune and inflammation: replication gap | 1 direct and 1 indirect sources; direction profile: unclear |

### Next-Study Design Recommendation

The next high-yield study for Influenza Vaccination Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Chen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:5]
- Yingyounyong 2025; tier=A1; directness=direct; endpoint=immune; direction=unclear; representative statistic=P = 0.008. [bundle:8]
- Wang 2025a; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:10]
- Wright 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.042. [bundle:12]
- Espersen 2025b; tier=A1; directness=direct; endpoint=frailty; direction=positive; representative statistic=P < 0.001. [bundle:25]
- Wang 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:28]
- Li 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:33]
- Hansen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:38]
- Lin 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:41]
- Katangwe-Chigamba 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.045. [bundle:43]

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Chen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=69. [bundle:5]
- Yingyounyong 2025: outcome=immune; directness=direct; tier=A1; direction=unclear; claims=59. [bundle:8]
- Wang 2025a: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=56. [bundle:10]
- Wright 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=49. [bundle:12]
- Espersen 2025b: outcome=frailty; directness=direct; tier=A1; direction=positive; claims=31. [bundle:25]
- Wang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=26. [bundle:28]
- Li 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=22. [bundle:33]
- Hansen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=18. [bundle:38]
- Lin 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=14. [bundle:41]
- Katangwe-Chigamba 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=9. [bundle:43]
- Zhang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=9. [bundle:44]
- Xie 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=5. [bundle:48]
- Alotaibi 2026: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=21. [bundle:34]
- Liu 2025: outcome=longevity; directness=review; tier=B1; direction=positive; claims=7. [bundle:45]
- Hosseini 2026: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:49]
- Streeter 2022: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:50]
- Sun 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=positive; claims=106. [bundle:1]
- Espersen 2025a: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=97. [bundle:2]
- Wen 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=93. [bundle:3]
- Guo 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=76. [bundle:4]
- Fortunato 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=68. [bundle:6]
- Luo 2026: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=61. [bundle:7]
- Yang 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=57. [bundle:9]
- Tadount 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=52. [bundle:11]
- Szilagyi 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:13]
- Wang 2025b: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:14]
- Wang 2025c: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=46. [bundle:15]
- Appel 2025: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=44. [bundle:16]
- Jin 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=43. [bundle:17]
- Alshagrawi 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=34. [bundle:19]
- Rocinova 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=33. [bundle:20]
- Papagiannis 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=32. [bundle:21]
- Jiang 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=31. [bundle:24]
- Krishnan 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31. [bundle:23]
- Wei 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=31. [bundle:22]
- Chaves 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=28. [bundle:26]
- Chiu 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=26. [bundle:27]
- Hu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=26. [bundle:29]
- Alshahrani 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=25. [bundle:30]
- Andrew 2004: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=24. [bundle:53]

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Incalzi 2024 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Incalzi 2024 (null on mortality) — partial conflict [bundle:34] [bundle:52]
- Severity 4 null vs positive: Luo 2026 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Luo 2026 (null on mortality) — partial conflict [bundle:7] [bundle:34]
- Severity 3 indirectness gap: Wang 2024 vs Hu 2024; Wang 2024 (direct, A1) vs Hu 2024 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:29]
- Severity 3 indirectness gap: Wang 2024 vs Papagiannis 2024; Wang 2024 (direct, A1) vs Papagiannis 2024 (review) on contextual other — direct vs indirect must be kept separate [bundle:21] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Alshagrawi 2025; Wang 2024 (direct, A1) vs Alshagrawi 2025 (review) on contextual other — direct vs indirect must be kept separate [bundle:19] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Mora 2025; Wang 2024 (direct, A1) vs Mora 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:37]
- Severity 3 indirectness gap: Wang 2024 vs Szilagyi 2025; Wang 2024 (direct, A1) vs Szilagyi 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:13] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Wang 2025b; Wang 2024 (direct, A1) vs Wang 2025b (indirect) on contextual other — direct vs indirect must be kept separate [bundle:14] [bundle:28]

## References

- **Sun 2025.** _Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study._ Vaccines, 2025. DOI: 10.3390/vaccines13020164 PMID: 40006711.
- **Espersen 2025a.** _Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial._ European Heart Journal Open, 2025. DOI: 10.1093/ehjopen/oeaf160 PMID: 41536962.
- **Wen 2025.** _Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2468074 PMID: 39993940.
- **Guo 2025.** _Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference._ eClinicalMedicine, 2025. DOI: 10.1016/j.eclinm.2025.103449 PMID: 40896461.
- **Chen 2025.** _Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial._ BMC Medicine, 2025. DOI: 10.1186/s12916-025-04156-1 PMID: 40468328.
- **Fortunato 2025.** _Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023._ International Journal of Health Geographics, 2025. DOI: 10.1186/s12942-025-00446-2 PMID: 41455971.
- **Luo 2026.** _Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study._ Virus Research, 2026. DOI: 10.1016/j.virusres.2026.199700 PMID: 41643751.
- **Yingyounyong 2025.** _A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study._ Clinical and Experimental Medicine, 2025. DOI: 10.1007/s10238-025-01639-6 PMID: 40205278.
- **Yang 2024.** _Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis._ Vaccines, 2024. DOI: 10.3390/vaccines12111259 PMID: 39591162.
- **Wang 2025a.** _A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China._ NPJ Digital Medicine, 2025. DOI: 10.1038/s41746-025-02137-5 PMID: 41310039.
- **Tadount 2025.** _Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review._ Canada Communicable Disease Report, 2025. DOI: 10.14745/ccdr.v51i09a02 PMID: 41393795.
- **Wright 2025.** _Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial._ Journal of Public Health (Oxford, England), 2025. DOI: 10.1093/pubmed/fdaf023 PMID: 40158203.
- **Szilagyi 2025.** _Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2025.26514 PMID: 40802184.
- **Wang 2025b.** _Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study._ Journal of Medical Internet Research, 2025. DOI: 10.2196/76849 PMID: 40921067.
- **Wang 2025c.** _Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study._ The Journal of Clinical Hypertension, 2025. DOI: 10.1111/jch.70044 PMID: 40751465.
- **Appel 2025.** _The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia._ Journal of the American Geriatrics Society, 2025. DOI: 10.1111/jgs.19392 PMID: 40123175.
- **Jin 2026.** _Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1798398 PMID: 42273673.
- **Pedersen 2024.** _INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2024-084808 PMID: 38950997.
- **Alshagrawi 2025.** _Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2477954 PMID: 40068961.
- **Rocinova 2026.** _Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review._ Journal of Alzheimer's Disease, 2026. DOI: 10.1177/13872877261420240 PMID: 41736221.
- **Papagiannis 2024.** _Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review._ Journal of Clinical Medicine, 2024. DOI: 10.3390/jcm13113029 PMID: 38892740.
- **Jiang 2025.** _Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2574732 PMID: 41128133.
- **Espersen 2025b.** _Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial._ The Journal of Infectious Diseases, 2025. DOI: 10.1093/infdis/jiaf420 PMID: 40796377.
- **Wei 2026.** _The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2025.1701127 PMID: 41640676.
- **Krishnan 2026.** _Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India._ Influenza and Other Respiratory Viruses, 2026. DOI: 10.1111/irv.70264 PMID: 42062199.
- **Chaves 2026.** _Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022._ Epidemiologia e Serviços de Saúde: Revista do Sistema Unico de Saúde do Brasil, 2026. DOI: 10.1590/S2237-96222026v35e20250561.en PMID: 41880426.
- **Wang 2024.** _Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-076194 PMID: 38367966.
- **Hu 2024.** _Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake._ JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.3098 PMID: 38526493.
- **Chiu 2025.** _Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study._ BMC Gastroenterology, 2025. DOI: 10.1186/s12876-025-03665-w PMID: 39994561.
- **Alshahrani 2025.** _Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj._ Vaccines, 2025. DOI: 10.3390/vaccines13111134 PMID: 41295507.
- **Bukhbinder 2026.** _Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination._ Neurology, 2026. DOI: 10.1212/WNL.0000000000214782 PMID: 41921123.
- **McConeghy 2025.** _Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2024.52677 PMID: 39745702.
- **Andrew 2004.** _Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging._ BMC Public Health, 2004. DOI: 10.1186/1471-2458-4-36 PMID: 15306030.
- **Li 2025.** _Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial._ BMC Public Health, 2025. DOI: 10.1186/s12889-025-23301-2 PMID: 40610910.
- **Alotaibi 2026.** _Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Vaccines, 2026. DOI: 10.3390/vaccines14040309 PMID: 42042785.
- **Wang 2026.** _Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China._ Vaccines, 2026. DOI: 10.3390/vaccines14040338 PMID: 42042813.
- **Leung 2025.** _The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2516314 PMID: 40497727.
- **Mora 2025.** _Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns._ BMJ Public Health, 2025. DOI: 10.1136/bmjph-2025-002698 PMID: 40791265.
- **Hansen 2025.** _Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/63938 PMID: 39998878.
- **Dehesh 2025.** _Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD._ Vaccines, 2025. DOI: 10.3390/vaccines13050472 PMID: 40432084.
- **Lin 2024.** _Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial._ Healthcare, 2024. DOI: 10.3390/healthcare12232361 PMID: 39684983.
- **Bonduelle 2025.** _Boosting effect of high-dose influenza vaccination on innate immunity among elderly._ JCI Insight, 2025. DOI: 10.1172/jci.insight.184128 PMID: 40036077.
- **Yang 2025.** _Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation._ BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06695-x PMID: 41315989.
- **Zhang 2024.** _Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China._ Trials, 2024. DOI: 10.1186/s13063-024-08452-8 PMID: 39587669.
- **Katangwe-Chigamba 2025.** _Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England._ BMC Health Services Research, 2025. DOI: 10.1186/s12913-025-13298-0 PMID: 40835927.
- **Liu 2025.** _Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials._ Travel Med Infect Dis, 2025. DOI: 10.1016/j.tmaid.2024.102793 PMID: 39710016.
- **Pagkozidis 2026.** _Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece._ Vaccines, 2026. DOI: 10.3390/vaccines14050458 PMID: 42188828.
- **Xie 2024.** _Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-080115 PMID: 38609315.
- **Abbasian 2025.** _Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran._ BMC Infectious Diseases, 2025. DOI: 10.1186/s12879-025-12392-2 PMID: 41449332.
- **Streeter 2022.** _Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study._ J Clin Epidemiol, 2022. DOI: 10.1016/j.jclinepi.2022.06.018 PMID: 35817230.
- **Hosseini 2026.** _Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis._ Am J Cardiol, 2026. DOI: 10.1016/j.amjcard.2026.03.040 PMID: 41951138.
- **Blandi 2026.** _From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention._ Aging Clinical and Experimental Research, 2026. DOI: 10.1007/s40520-026-03323-5 PMID: 41543642.
- **Incalzi 2024.** _Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion._ Internal and Emergency Medicine, 2024. DOI: 10.1007/s11739-023-03456-9 PMID: 37891453.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "1c78fffe-05e3-4d3c-8893-210680e5a307",
  "title": "Research Synthesis: Influenza Vaccination Effects \u2014 full paper"
}